2017 American Society of Clinical Oncology Annual Meeting*

In the phase III LION trial, systemic pelvic and para-aortic lymphadenectomy offered no survival benefit and increased postoperative morbidity and mortality in patients with advanced ovarian cancer, macroscopic complete resection, and clinically/radiographically negative lymph nodes.

Combination RT + CT improved 5-year failure-free survival by 11% in patients with stage III disease.

Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.

No detrimental effect on HRQoL, significant improvement in patient-centered benefits with olaparib vs placebo despite higher olaparib-associated toxicity.